Long-term effect of interferon and Glatiramer acetate in real-world settings use on multiple sclerosis disability progression: Input of time-dependent propensity score

Mathilde Lefort (1, 2, 3) , Yohann Foucher (4, 5) , Rémi Lenain (5, 6) , Sandra Vukusic (7, 8) , Gilles Edan (3, 9) , Emmanuelle Leray (1, 2, 3)

1 REPERES - Recherche en Pharmaco-épidémiologie et Recours aux Soins
2 EHESP - École des Hautes Études en Santé Publique [EHESP]
3 CIC - Centre d'Investigation Clinique [Rennes]
4 CHU Nantes - Centre hospitalier universitaire de Nantes
5 SPHERE - MethodS in Patients-centered outcomes and HEalth ResEarch
6 CHRU Lille - Centre Hospitalier Régional Universitaire [Lille]
7 UCBL - Université Claude Bernard Lyon 1
8 Hôpital Edouard Herriot [CHU - HCL]
9 Service de Neurologie [CHU Rennes]

Keywords: Glatiramer acetate; Multiple sclerosis (MS); Interferon

Domains: Life Sciences [q-bio]

Mathilde Lefort, Yohann Foucher, Rémi Lenain, Sandra Vukusic, Gilles Edan, et al.. Long-term effect of interferon and Glatiramer acetate in real-world settings use on multiple sclerosis disability progression: Input of time-dependent propensity score. Pharmacoepidemiology and Drug Safety, 2019, 28, pp.217-218. ⟨hal-02302564⟩